Cellectar Biosciences, Inc. (CLRB)
Automate Your Wheel Strategy on CLRB
With Tiblio's Option Bot, you can configure your own wheel strategy including CLRB - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CLRB
- Rev/Share 0.0
- Book/Share 0.2091
- PB 2.0144
- Debt/Equity 0.0575
- CurrentRatio 2.4736
- ROIC -4.5799
- MktCap 16625628.0
- FreeCF/Share -1.0349
- PFCF -0.3486
- PE -0.6774
- Debt/Assets 0.0296
- DivYield 0
- ROE -1.9598
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 3
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | CLRB | Ladenburg Thalmann | -- | Buy | -- | $13 | Dec. 5, 2024 |
News
Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules
Published: June 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
FLORHAM PARK, N.J., June 05, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the entry into definitive agreements to raise $2.5 million from the sale of shares of the company's common stock priced at-market for Nasdaq purposes. The closing of the offering is expected to occur on or about June 6, 2025, subject to satisfaction of customary closing conditions.
Read More
4 Medical Product Stocks to Watch From a Challenging Industry
Published: May 21, 2025 by: Zacks Investment Research
Sentiment: Negative
The U.S. government's tariff imposition, especially on China, is likely to keep supply chains under pressure for the Zacks Medical Products industry. PODD, MGNX, CLRB and ALUR reflect the favorable fundamentals.
Read More
Cellectar Biosciences Inc. (CLRB) Q1 2025 Earnings Call Transcript
Published: May 13, 2025 by: Seeking Alpha
Sentiment: Neutral
Cellectar Biosciences Inc. (NASDAQ:CLRB ) Q1 2025 Earnings Conference Call May 13, 2025 8:30 AM ET Company Participants Jim Caruso - President and CEO Chad Kolean - CFO Jarrod Longcor - COO Anne Marie Fields - IR, Managing Director, Precision AQ Conference Call Participants Aydin Huseynov - Ladenburg Thalmann Operator Ladies and gentlemen, thank you for standing by, and welcome. At this time all participants are in listen-only mode.
Read More
Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Tuesday, May 13, 2025
Published: May 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
FLORHAM PARK, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the Company will report financial results for the first quarter ended March 31, 2025, and provide a corporate update on May 13, 2025, at 8:30 a.m. Eastern Time.
Read More
Cellectar Announces Plan to Explore Strategic Alternatives
Published: April 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
FLORHAM PARK, N.J., April 30, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the company will explore a full range of strategic alternatives to advance its promising platform and radiopharmaceutical drug development pipeline to maximize stockholder value. Strategic alternatives under consideration may include, but are not limited to mergers, acquisitions, partnerships, joint ventures, licensing arrangements or other strategic transactions. The company's board of directors has approved the engagement of Oppenheimer & Co. Inc. to serve as exclusive …
Read More
4 Medical Product Stocks to Buy From a Challenging Industry
Published: April 17, 2025 by: Zacks Investment Research
Sentiment: Positive
The U.S. government's tariff imposition, especially on China, is likely to keep supply chains under pressure for the Zacks Medical Products industry. PODD, MGNX, CLRB and ALUR are likely to gain from the favorable factors.
Read More
Is Cellectar Biosciences (CLRB) Stock Outpacing Its Medical Peers This Year?
Published: March 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Here is how Cellectar Biosciences, Inc. (CLRB) and Cencora (COR) have performed compared to their sector so far this year.
Read More
Cellectar Biosciences Inc. (CLRB) Q4 2024 Earnings Call Transcript
Published: March 13, 2025 by: Seeking Alpha
Sentiment: Neutral
Cellectar Biosciences Inc. (NASDAQ:CLRB ) Q4 2024 Earnings Conference Call March 13, 2025 8:30 AM ET Company Participants Anne Marie Fields – Managing Director-Precision AQ Jim Caruso – President and Chief Executive Officer Chad Kolean – Chief Financial Officer Jarrod Longcor – Chief Operating Officer Conference Call Participants Jonathan Aschoff – ROTH Operator Ladies and gentlemen, thank you for standing by, and welcome. At this time all participants are in listen-only mode.
Read More
About Cellectar Biosciences, Inc. (CLRB)
- IPO Date 2005-11-10
- Website https://www.cellectar.com
- Industry Biotechnology
- CEO Mr. James V. Caruso
- Employees 11